This single-arm, open-label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2À) advanced breast cancer evaluated the efficacy, safety, and pharmacokinetics of first-line palbociclib (125 mg once daily, 3 weeks on/1 week off) coadministered with letrozole (2.5 mg once daily). Primary endpoint of investigator-assessed 1-year progression-free survival (PFS) probability was 75.0% (90% CI, 61.3%-84.4%), far surpassing the 40% lower limit of the 90% CI supporting efficacy. Median duration of treatment was 438 days. Among secondary efficacy measures, median PFS was not reached (95% CI, 16.7: not estimable), 17/42 patients (40.5%) had an objective response, 36/42 (85.7%) maintained disease control, and 27/42 (64.3%) remained in follow-up. Median overall survival was not reached, and 1-year survival probability was 92.9% (95% CI, 79.5%-97.6%). Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steadystate mean area under the plasma concentration-time curve over the dosing interval [s] and mean maximum plasma concentration were 1979 ngÁh/mL and 124.7 ng/mL, respectively. For day 15 plasma samples from cycles 1 and 2, geometric mean of the within-patient mean trough concentration was 90.1 ng/mL.
| INTRODUCTION
The incidence of breast cancer in Japanese women increased 46% from 1995 to 2015, 1 and it is now the most common cancer and the fifth leading cause of cancer-related deaths among Japanese women. 2 Globally, between 5% and 10% of breast cancers are metastatic at the time of diagnosis, 3 and ABC, including recurrent disease and mBC, is incurable, 4 posing a significant public health burden and considerable treatment challenges. 5 For postmenopausal women with HR+ ABC, endocrine therapy with agents such as aromatase inhibitors (eg, anastrozole, letrozole, or exemestane) is the standard first-line treatment 6 and is recommended by the Japanese Breast Cancer Society treatment guidelines. 7 However, current first-line endocrine therapy alone may provide only modest benefit in patients with HR+ ABC, and some patients may not respond at all, 6 indicating the need for new treatment options. In a randomized phase III trial of exemestane vs anastrozole as first-line therapy in Japanese women with HR+ ABC, median time to progression was approximately 12 months in each group. 8 Thus, there is interest in improving outcomes by combining first-line endocrine therapy with other agents.
Palbociclib is a potent, orally active, highly selective inhibitor of CDK4/6; it actively arrests cell cycle progression from the G1 phase to the S phase to inhibit DNA synthesis and the pathologic cellular proliferation characteristic of breast malignancies. [9] [10] [11] Palbociclib showed antiproliferative activity alone and synergistic activity with tamoxifen in ER+ luminal breast cancer cell lines. 10 In clinical trials in non-Japanese patients with retinoblastoma protein-positive solid tumors, single-agent palbociclib showed antitumor efficacy with an acceptable safety profile and was well tolerated. 12, 13 In an openlabel, phase II PALOMA-1 trial, efficacy and safety of first-line letrozole (2.5 mg QD) alone or in combination with palbociclib (125 mg QD, 3 weeks on, 1 week off [3/1 schedule]) was investigated in non-Japanese postmenopausal women with ER+ and HER2À ABC. 14 Median PFS was significantly longer with combination therapy than with letrozole alone (20.2 vs 10.2 months, respectively; HR, 0.49; 95% CI, 0.32-0.75; one-sided P = .0004). AEs with combination therapy were predictable and manageable; neutropenia was the most commonly reported AE. 14 These findings were confirmed in the phase III PALOMA-2 trial in postmenopausal women with ER+/ HER2À ABC who received letrozole with or without palbociclib (3/1 schedule) as first-line therapy. 15 Consistent with PALOMA-1, median PFS was significantly longer with combination therapy than with letrozole monotherapy (24.8 vs 14.5 months; HR, 0.58; 95% CI, 0.46-0.72; two-sided P < .001). AEs were similar to those reported in the PALOMA-1 trial, with uncomplicated neutropenia being the most commonly reported toxicity. 15 Based on these findings, palbociclib was approved in the USA and Europe for the treatment of HR+/HER2À mBC or ABC in combination with an aromatase inhibitor as initial endocrine-based therapy. 16, 17 To investigate the efficacy, PK, and safety of palbociclib plus letrozole in Japanese patients, a phase I/II study was conducted in postmenopausal Japanese women with ER+/HER2À ABC. 18 In part 1 of the phase I dose-finding study, single-agent palbociclib was given to patients with advanced solid tumors that were refractory to standard therapy. Maximum tolerated dose of palbociclib was 125 mg, and safety findings were consistent with previous studies. 18 In part 2, palbociclib plus letrozole (same dosage regimen as in PALOMA-1 and PALOMA-2 trials) was assessed as first-line therapy in postmenopausal Japanese patients with ER+/HER2À ABC. There was no evidence of a drug-drug interaction between palbociclib and letrozole; thus, the recommended palbociclib dosage in Japanese patients is 125 mg QD (3/1 schedule) in combination with letrozole 2.5 mg daily, 18 the same dosing regimen used to treat Western patients.
The PALOMA-1 trial did not include Japanese patients, and the results of the PALOMA-2 trial were not available when this study started. Thus, the primary objective of the phase II portion of this phase I/II study was to evaluate the efficacy of palbociclib in combination with letrozole using 1-year PFS probability in postmenopausal Japanese patients with ER+/HER2À ABC.
| MATERIALS AND METHODS

| Study design
This was the phase II portion of a phase I/II, single-country, non-randomized, open-label, single-arm, multicenter study in Japanese patients (NCT01684215). The phase I part of this study has been published. 18 The primary objective of the phase II part of the study was to evaluate the efficacy of palbociclib in combination with letrozole using 1-year PFS probability in postmenopausal Japanese patients with ER+/HER2À ABC. There were several secondary objectives. We assessed ORR, DCR, DOR, PFS, 1-year survival, and OS. Additional assessments included safety and tolerability, evaluation of health-related quality of life (not reported), determination of plasma C trough of palbociclib combined with letrozole in all patients, and evaluation of the full PK profile of palbociclib in a subset of treated patients (n = 6). We also characterized biomarkers of tumor sensitivity and/or resistance in tumor tissue samples, such as the Ki-67 index, for which a 20% cutoff has been determined to be optimal (a significant factor for overall survival), or the most effective prognostic factor for luminal/HER2À breast cancer based on a study of 4329 Japanese patients with primary breast cancer. 19 The study protocol was approved by the Institutional Review
Board at each participating center, and written informed consent was obtained from all patients before enrollment. The study was conducted according to applicable local laws and regulatory require- evaluations were based on investigator assessments. OS was determined every 6 months from the last dose of study treatment.
| Pharmacokinetics
A subset of 6 patients underwent intensive PK sampling, and blood samples were taken on cycle 1/day 15 at predose and at 1, 2, 4, 6, 8, 10, and 24 hours after dosing, then at predose on cycle 2/day 15.
For this subset, plasma concentration-time data obtained after study drug administration on cycle 1/day 15 were analyzed using noncompartmental analysis methods to determine the following PK parameters: C max , t max , AUC s , and CL/F. For assessment of palbociclib plasma C trough , blood samples from all patients were collected on day 15 of cycles 1 and 2 before giving study drug. Plasma samples were analyzed for palbociclib concentrations using a validated HPLC method with tandem mass spectrometry at PPD Development (Richmond, VA, USA). Lower limit of quantification for palbociclib was 1.00 ng/mL. 
| Statistical analyses
Primary endpoint of this study was the 1-year PFS probability of the lower limit of the 90% CI exceeding 40%, which would correspond to a median PFS of 9 months, assuming that PFS had an exponential distribution. Sample size for this study was 32 patients to meet the above criteria with a >80% probability based on the assumption that median PFS for patients receiving palbociclib plus letrozole was Objective response rate and DCR were estimated. DOR was based on the subset of patients in the FAS who had an objective response (CR or PR) and was defined as the time from first objective response to first objective PD or death. OS was estimated using the Kaplan-Meier method, and 1-year OS was calculated in the same way as for 1-year PFS.
The PK analysis set was defined as all patients with ≥1 PK parameter of primary interest in ≥1 PK sampling period. PK parameters are presented using descriptive statistics. For the full palbociclib PK profile subset (n = 6), plasma concentration-time data obtained after giving palbociclib on cycle 1/day 15 were also summarized descriptively and are presented graphically. Steady-state palbociclib C trough values for all patients were calculated as geometric mean and geometric %CV.
The study is still ongoing for the collection of survival data.
3 | RESULTS
| Patient disposition
Forty-three patients were enrolled at 16 centers in Japan, and patient accrual for this study was conducted between June 24, 2014 and Figure 1B ). (53.5%-91.1%), respectively. Median PFS was not reached in any of these subgroups ( Figure 2B ).
In patients with tumor biopsies expressing Ki-67-positive cells ≤20% vs >20%, median PFS was not reached in the former and was reached at 16.7 months (95% CI, 9.3-NE) in the latter ( Figure 2C ).
Median PFS was not reached in patients who had a dose reduction and was 16.7 months (95% CI, 8.1-NE) in patients who did not have a dose reduction ( Figure 2D ).
The ORR was 40.5% (95% CI, 25.6%-56.7%) and the DCR was 85.7% (95% CI: 71.5%-94.6%); no patient had achieved a CR. In the response evaluable analysis set, which was in patients with measurable disease, ORR was 47.2% (95% CI, 30.4%-64.5%) and DCR was 83.3% (95% CI, 67.2%-93.6%). Median DOR was not reached (95% CI, 6.5 months-NE). Only 3 OS events (7.1%) had occurred, and median OS was not reached. Most patients (90.5%) were still in follow up for OS at the data cutoff. Survival probability at 12 months was 92.9% (95% CI, 79.5%-97.6%).
| Pharmacokinetics
For the PK analyses, data cutoff was September 25, 2015. Palbociclib steady-state mean AUC s and C max were 1979 ngÁh/mL and 124.7 ng/mL, respectively, for the subset of patients who underwent intensive PK sampling (n = 6; Table 2 ). Interpatient variability (geometric %CV) of palbociclib steady-state AUC s (ngÁh/mL) and C max (ng/mL) were 16% and 26%, respectively. Median palbociclib steadystate concentration-time profile on cycle 1/day 15, when coadministered with letrozole, is shown in Figure 3 (n = 6).
Mean palbociclib C trough in combination with letrozole on cycle 1/day 15 and cycle 2/day 15 were determined for all patients in the PK population (n = 38; Table 3 ). Mean C trough values on each Prior therapies for primary diagnosis, yes, n (%) 
| Treatment-related adverse events
The most common treatment-related AEs (by clustered preferred term) were neutropenia (100% of patients), stomatitis (73.8%), and leukopenia (71.4%), and the most common treatment-related grade 3 or 4 AEs were neutropenia (90.5%), and leukopenia (50.0%; Table 5 ).
There was 1 case of treatment-related grade 3 febrile neutropenia (onset day 18) that resolved by day 29.
| Serious adverse events and deaths
Serious AEs were reported in 3 patients (7.1%) and included vomiting, malaise, dizziness, and subarachnoid hemorrhage (in 1 patient), febrile neutropenia (1 patient), and cerebral hemorrhage (1 patient).
Two of these events were considered treatment-related (subarachnoid hemorrhage and febrile neutropenia). The patient who experienced the treatment-related subarachnoid hemorrhage died; the last doses of palbociclib and letrozole were given 12 and 5 days, respectively, before death.
Treatment-related AEs leading to permanent discontinuation of treatment were reported in 3 patients (7.1%) who permanently discontinued palbociclib only (neutropenia in each patient) and in 3 patients (7.1%) who discontinued both palbociclib and letrozole (malaise, ALT and AST increased, and subarachnoid hemorrhage in 1 patient each; Table S1 ). Treatment-related AEs leading to dose reductions were reported in 25 patients (59.5%); the most common reason was neutropenia (20 patients [47.6%]).
No patients had a QTc interval of ≥500 ms, and there were no clinically relevant changes in vital signs during the study. Thus, the expected efficacy of palbociclib plus letrozole was observed because the lower limit of the 90% CI exceeded 40%. At the later October 31, 2016 data cutoff, 1-year PFS probability was 75.6% (90% CI, 62.4%-84.7%). The 1-year PFS probability in this study was similar to the results in the PALOMA-1 and PALOMA-2 studies. 21 Median PFS in patients in the PALOMA-1 study was 
| DISCUSSION
(B)
F I G U R E 1 Investigator-assessed progression-free survival in Japanese postmenopausal women with estrogen receptor-positive/ human epidermal growth factor receptor 2-negative advanced breast cancer receiving palbociclib plus letrozole (N = 42) at the (A) March 4, 2016 data cutoff and (B) October 31, 2016 data cutoff. mPFS, median progression-free survival; NE, not estimable; NR, not reached reached 16.7 and 21.7 months at the respective cutoff dates. Efficacy data for this study after a longer duration of follow up will be further evaluated.
In the current study, subgroup analyses provided valuable insights into the effects of baseline characteristics and study treatment characteristics on PFS. One-year PFS probability was higher in patients with non-visceral vs visceral metastases, in patients with de novo metastatic disease or a disease-free interval >12 months vs ≤12 months. For median PFS, the sample size may have precluded a conclusive result for the subgroup analysis by disease-free interval.
A similar trend, suggesting that de novo metastatic disease or a disease interval >12 months had a favorable effect, was observed in a subgroup analyses of PALOMA-2 patients. 22 In PALOMA-2, a subgroup analysis suggested palbociclib plus letrozole improved PFS regardless of baseline characteristics, including by disease sites or disease-free interval. 22 In this Japanese study, the Kaplan-Meier plot was similar in patients who required a dose reduction on treatment vs patients who did not, suggesting palbociclib dose reductions, which were predominantly from 125 to 100 mg, appear not to affect efficacy. Because these data are still immature, the impact of dose reduction will be further investigated when additional follow-up data are available. At the initial data cutoff, 40.5% of patients had an objective response to treatment and the median DOR had not been reached.
These findings are comparable to the objective responses of 43%
and 42% in the PALOMA-1 and PALOMA-2 trials, respectively.
Moreover, the proportion of patients with disease control in the current study (85.7%) was similar to those in PALOMA-1 (81%) and PALOMA-2 (84.9%). 14, 15 In the current study, median OS also had not been reached by When coadministered with letrozole, the full PK analysis conducted in 6 Japanese patients in the current study showed a PK profile that was remarkably similar to that reported in the PALOMA-1 study in non-Japanese patients. 25 The C trough of plasma palbociclib in all patients was 89.4 and 86.8 ng/mL on day 15 of cycles 1 and 2, respectively. These data are highly consistent with the exploratory findings from the phase I portion of this study when the plasma palbociclib C trough was 72.8 ng/mL after multiple oral doses on day 8 of cycles 1 and 2 when coadministered with letrozole. 18 In the phase II portion of PALOMA-1, the C trough of plasma palbociclib was 63.5 and 62.4 ng/mL on day 14 of cycles 1 and 2, respectively, collectively indicating that the plasma palbociclib mean C trough appeared to be slightly higher in Japanese patients; however, the distribution of plasma C trough in this study and PALOMA-1 overlap.
In the current study, palbociclib in combination with letrozole was well tolerated. The most commonly reported AE was uncomplicated neutropenia, and AEs were manageable by implementing palbociclib dose interruptions or reductions and/or standard medical therapy. These findings are consistent with the known safety profile Time to first event (dose reduction/dose interruption) = (start date of first occurrence minus first dose date of cycle 1) + 1; for dose interruption, time could not be calculated for some patients as a result of unknown dates for missing doses. e 0 mg given on a planned dosing day. Could not be calculated for some patients as a result of unknown dates for missing doses. f During total cycles. g Overall relative dose intensity = (sum of overall cycles of actual total dose per cycle/sum over all cycles of the actual number of weeks in cycle)/(sum over all cycles of intended total dose per cycle/sum over all cycles of intended number of weeks per cycle) 9 100. -, not applicable because a dose reduction for letrozole was not allowed per the study protocol.
T A B L E 5 Investigator-assessed treatment-related adverse events of all grades and grades 3/4 occurring in ≥10% of patients (all cycles) in Japanese postmenopausal patients with ER+/HER2À ABC receiving palbociclib plus letrozole Clustered preferred terms (PTs) were used to represent multiple PTs as follows: Infections included any event with a PT that is part of the Med-DRA system organ class "Infections and Infestations," and in this study, related PTs included angular cheilitis, cellulitis, gingivitis, laryngitis, lip infection, nasopharyngitis, oral herpes, otitis media, pharyngitis, or upper respiratory tract infection; Leukopenia included the PT leukopenia or white blood cell count decreased; Neutropenia included the PT neutropenia or neutrophil count decreased; Rash included the PT rash, rash maculopapular, dermatitis, dermatitis or acneiform; Stomatitis included the PT cheilitis, glossitis, oropharyngeal pain, or stomatitis; Thrombocytopenia included the PT thrombocytopenia or platelet count decreased. In conclusion, first-line therapy with palbociclib plus letrozole was effective and AEs were manageable in postmenopausal Japanese women with advanced ER+/HER2À breast cancer. Palbociclib in combination with letrozole should be considered as a first-line treatment option in Japanese patients in this population.
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